GNI Group Swings to Non-Consolidated Loss on Absence of One-Off Gain and Forward Transaction Hit

GNI Group ( (JP:2160) ) has issued an update.

GNI Group Ltd., a biopharmaceutical company listed on the TSE Growth market, reported a sharp year-on-year swing in its non-consolidated performance for the fiscal year ended December 31, 2025, under Japanese GAAP. The company’s standalone results are sensitive to intragroup transactions, particularly with its U.S. subsidiaries, which can create substantial temporary gains or losses that differ from the underlying operating picture.

For 2025, GNI’s non-consolidated ordinary income fell to a loss of JPY 1.59 billion and net income dropped to a loss of JPY 1.33 billion, compared with profits of JPY 5.90 billion in the previous year, with net income per share reversing from JPY 118.06 to a loss of JPY 25.45. Management attributed the decline mainly to the absence of a prior one-off gain from the reversal of about JPY 6.02 billion in doubtful-account provisions tied to GNI USA and Gyre Therapeutics shares, and to a new one-time loss of JPY 630 million on a forward transaction, highlighting the impact of non-recurring items on the company’s headline earnings for investors and other stakeholders.

The most recent analyst rating on (JP:2160) stock is a Hold with a Yen2600.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.

More about GNI Group

GNI Group Ltd. is a Japan-listed biopharmaceutical company on the TSE Growth market, focused on developing and commercializing innovative therapeutic products through a network of subsidiaries such as GNI USA and Gyre Therapeutics. The group’s operations involve cross-border financing and asset management structures that can generate significant one-off accounting effects on its standalone Japanese GAAP results.

Average Trading Volume: 1,371,545

Technical Sentiment Signal: Buy

Current Market Cap: Yen143.2B

Learn more about 2160 stock on TipRanks’ Stock Analysis page.